Ibrutinib-exposed tumor cells present their antigens to T cells. H11 tumor cells were incubated with ibrutinib (1 µM) for 24 hours and then cocultured with splenocytes or purified splenic T cells from mice that had been treated with the ibrutinib/CpG combination. IFN-γ production by CD3+/CD8+ T cells was measured by flow cytometry after 24 hours. The proportion of IFN-γ+ cells as a percentage of lymphocytes was calculated and shown as dot plots and as bar graphs. This response was higher when splenic APCs were present.